Tickers — J

13 tickers
Ranks this page's recent reports by score.
Jack Henry & Associates, Inc.
JKHY·Technology
S ★★★★★Strong Buy
Current$150.58
Target$184.60
Return+22.6%
Jul 28, 2026

Jack Henry pairs an impenetrable 92% recurring-revenue banking monopoly with accelerating, high-margin payment rails, providing unmatched EPS visibility via aggressive buybacks despite the slow headwind of regional bank consolidation.

Score
100
Jefferies Financial Group Inc.
JEF·Financials
A ★★★★Buy
Current$55.86
Target$74.40
Return+33.2%
Jul 28, 2026

Jefferies offers a rare convergence of explosive, bulge-bracket level market share capture temporarily obscured by the cyclical noise and legal overhangs of its legacy asset management portfolio.

Score
89
JBS N.V.
JBS·Consumer Staples
B ★★★Hold
Current$12.25
Target$18.59
Return+51.8%
Jul 25, 2026

JBS offers a compelling valuation discount and robust multi-protein diversification, but near-term headwinds from the U.S. beef cycle and escalating ESG litigation risks necessitate a cautious hold until margins visibly trough.

Score
76
J.B. Hunt Transport Services, Inc.
JBHT·Industrials
B ★★★Hold
Current$291.41
Target$310
Return+6.4%
Jul 22, 2026

Ride J.B. Hunt's powerful post-recession intermodal volume recovery and cost efficiencies, while exercising extreme caution regarding its stretched 41x P/E trailing valuation and heavy voluntary executive profit-taking.

Score
76
Johnson & Johnson
JNJ·Healthcare
B ★★★Hold
Current$253.04
Target$279.19
Return+10.3%
Jul 22, 2026

Johnson & Johnson offers a diversified, highly defensive healthcare compounder model with aggressive pipeline momentum, though massive talc litigation overhangs and Stelara's patent expiration warrant a cautious, valuation-disciplined entry strategy.

Score
75
JPMorgan Chase & Co.
JPM·Financials
A ★★★★Buy
Current$345.23
Target$375.00
Return+8.6%
Jul 22, 2026

JPMorgan Chase leverages unmatched scale and a fortress balance sheet to deliver 20%+ ROTCE, though its premium valuation demands sustained execution amidst normalizing consumer credit and macroeconomic shifts.

Score
86
Jazz Pharmaceuticals plc
JAZZ·Healthcare
A ★★★★Buy
Current$243.82
Target$285.00
Return+16.9%
Jul 16, 2026

Jazz Pharmaceuticals is successfully pivoting from a legacy sleep monopoly to a diversified oncology and epilepsy powerhouse, offering a massive margin of safety at a 9.5x forward P/E despite looming generic competition.

Score
87
James Hardie Industries plc
JHX·Materials
B ★★★Hold
Current$24.79
Target$28.46
Return+14.8%
Jul 13, 2026

The AZEK acquisition transforms James Hardie into an impenetrable exterior solutions monopoly capable of unprecedented margin expansion, though near-term upside is throttled by a suffocating debt load and a stagnant U.S. housing market.

Score
77
Jabil Inc.
JBL·Technology
A ★★★★Buy
Current$330.29
Target$435.00
Return+31.7%
Jul 12, 2026

Jabil is successfully pivoting from lower-margin consumer electronics to high-growth AI infrastructure and data center power management, driving significant margin expansion and robust cash flow.

Score
85
JD.com, Inc.
JD·Consumer Discretionary
A ★★★★Buy
Current$28.20
Target$39.80
Return+41.1%
Jul 12, 2026

JD.com presents a massive deep-value opportunity backed by a $13B net cash fortress and a dominant logistics moat, though near-term upside is capped by a brutal domestic e-commerce price war and macro stagnation.

Score
87
Joby Aviation, Inc.
JOBY·Industrials
B ★★★Hold
Current$9.00
Target$12.69
Return+41.0%
Jul 1, 2026

Joby Aviation pairs industry-leading FAA certification progress and a $2.5 billion fortress balance sheet with formidable Toyota manufacturing backing, though astronomical valuation multiples and extreme regulatory reliance demand a patient, risk-adjusted approach.

Score
76